Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy

Wu, Yu-Ting; Chen, Shou-Tung; Chen, Chih-Jung; Kuo, Yao-Lung; Tseng, Ling-Ming; Chen, Dar-Ren; Kuo, Shou-Jen; Lai, Hung-Wen

doi:10.1186/1477-7819-12-335

Table 1 Demographic data from identified studies in the literature and our cases ^a

From: Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy

Patient	Study	Age (yr)	Tumor size (cm)	Noted tumor duration (months)	Histology	TNM stage	Surgery	LN dissection	LN metastasis	Receptor status	C/T	H/T	R/T	Outcome
1	Kurosumi et al., 1994[14]	42	2 × 3	21	IDC		Ex	A
2	Sarela et al., 1995[15]	56	2 × 3	2	LCIS + IDC		MT	A	P
3	Shah et al., 1999[16]	45	2.5 × 2	3	LCIS	TisN0M0	Ex		N
4	Yano et al., 2001[17]	54	2		ILC	TisN0M0	Ex	A	N
5	Kuijper et al., 2002[18]	46	Multiple		DCIS + LCIS	TisN0M0	MT
6	Abe et al., 2004[19]	42	5.1 × 4.4	60	IDC		MT	A	P	ER-PR+	Yes	Yes	No
7	Stafyla et al., 2004[20]	27	3.4		LCIS	TisN0M0	Ex		N
8	Shin et al., 2006[21]	51	1.5 × 1	12	IDC		MT	S	N	ER+PR+
9	Yuen et al., 2007[22]	39	1.1		ILC		BCS
10	Yuen et al., 2007[22]	45	0.8		ILC		BCS
11	Borecky and Rickard, 2008[23]	64	1.2		IDC	T1bN0M0	BCS	S	N	ER+PR+
12	Borecky and Rickard, 2008[23]	80	4.5	600	IDC		BCS	S	N
13	Borecky and Rickard, 2008[23]	53	1.7	12	DCIS	TisN0M0	Ex	S	N
14	Gashi-Luci et al., 2009[24]	39	2.6 × 1.6		IDC		MT	A	N	ER-PR-				R
										HER2-
15	Khandelwal et al., 2009[25]	35	2 × 3	2	IDC		BCS	A	P	ER+PR+	Yes	Yes	Yes
										HER2-
16	Iyengar et al., 2009[26]	43	1.8	24	IDC		MT			ER-PR-
										HER2+
17	Rao et al., 2010[27]	30	4 × 2	1	IDC		MT	A	P	ER-PR-	Yes	No	Yes
										HER2-
18	Petersson et al., 2010[28]	49	3	48	IDC		Ex	S	N	ER+PR+
										HER2-
19	Kato et al., 2011[29]	42	1.5		DCIS	TisN0M0	BCS	S	N
20	Ooe et al., 2011[30]	46	2.4 × 1.7	60	DCIS	TisN0M0	BCS	S	N	ER+PR+	No	Yes	Yes
21	Tajima et al., 2011[31]	60	1.9 × 1.6	3	ILC		BCS			ER+PR+
										HER2-
22	Abu-Rahmeh et al., 2012[32]	69	5	180	IDC									Lung metastasis^b
23	Jahan et al., 2012[33]	55	5 × 4 × 3	240	IDC		MT
24	Butler et al., 2012[34]	46	0.8 × 0.8		ILC	T1bN0M0	Ex
25	Present study	39	2.7 × 2.7	24	IDC	T1aN0M0	BCS	S	N	ER+PR+	No	Nr	Nr
										HER2-
26	Present study	31	3.5 × 3.4	84	IDC	T1aN1M0	MT	A	P	ER+PR+	Yes	Yes	No
										HER2-
27	Present study	30	1.5 × 1.4		DCIS	TisN0M0	BCS			ER+PR+	No	Yes	No
										HER2-
28	Present study	63	1.2	0.5	DCIS	TisN0M0	BCS	S	N	ER+PR+	No	Yes	Yes
										HER2-
29	Present study	48	0.9	3	DCIS	TisN0M0	Ex	S	N		No	No	No
30	Present study	40	0.6	0	IDC	T1bN0M0	MT	S	N	ER +PR-	No	Yes	No

^aA, Axillary lymph node dissection level I/II/III; B, Benign; C/T, Chemotherapy; ER, Estrogen receptor; Ex, Excision; HER2, Human epidermal growth factor receptor 2 ; H/T, Hormone therapy; LN, Lymph node; M, Malignancy; MT, Mastectomy; N, Negative; Nr, Patient refuse; P, Positive; PR, Progesterone receptor; R, Recurrence; R/T, Radiotherapy; S, Sentinel lymph node dissection; TNM, Tumor, node, metastasis. ^bLung metastasis at diagnosis.

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us